[Autoimmune pancreatitis -- rituximab for the prevention of relapses?].
Frank
F
Lichert
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects; D010195:Pancreatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D012008:Recurrence; D000069283:Rituximab; D055502:Secondary Prevention; D013256:Steroids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D013256:Steroids; D000069283:Rituximab